Q1 2022 Results

Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis pipeline in Phase 1 Appendix Innovation: Clinical trials AAA603 AAA817 Solid tumors Code Name 177Lu-NeoB Ac-PSMA-617 ADPT01 ADPT01 DFF332 DFF332 DKY709 IAG933 IAG933 JDQ443 JDQ443 KAZ954 KAZ954 Solid tumors NIS793 NIS793, spartalizumab TGFB1 inhibitor Solid tumors NIZ985 NIZ985, spartalizumab IL-15 agonist Solid tumors NZV930 NZV930, spartalizumab, NIR178 CD73 antagonist Solid tumors PDR001 spartalizumab PD1 inhibitor Solid tumors (combo) TNO155 TNO155 SHP2 inhibitor Solid tumors (combo) VPM087 gevokizumab WNT974 WNT974 spartalizumab IL-1 beta antagonist Porcupine inhibitor Colorectal cancer, 1st line Solid tumors Hematology Mechanism Indication(s) Code Name Radioligand therapy target GRPR Radioligand therapy target PSMA Multiple solid tumors ADPT03 ADPT03 KRAS Inhibitor DKY709spartalizumab HIF2A inhibitor Novel immunomodulatory agent Mesothelioma KRAS G12C mutated solid tumors Metastatic castration-resistant prostate cancer Colorectal cancer (combos) Renal cell carcinoma Cancers HDM201 HDM201 + MBG453, venetoclax JBH492 JBH492 JEZ567 JEZ567 MAK683 MAK683 MBG453 sabatolimab MIK665 MIK665 VAY736 ianalumab + ibrutinib VOB560 VOB560 WVT078 WVT078 YTB323 YTB323 Immunology Code Name FIA586 FIA586 MHS552 MHS552 MHV370 MHV370 NGI226 NG1226 Neuroscience Code NIO752 Others Code Name Global Health Mechanism Indication(s) Non-alcoholic steatohepatitis (NASH) EYU688 Autoimmune indications KAF156 EYU688 ganaplacide Systemic lupus erythematosus Tendinopathy INE963 INE963 Respiratory & Allergy Name NIO752 Mechanism Indication(s) Tau antagonist Progressive supranuclear palsy 38 Investor Relations | Q1 2022 Results LTP001 LTP001 NCJ424 NCJ424 Ophtalmology MHU650 MHU650 References Abbreviations 28 lead indications Lead indication Mechanism BCL11A MDM2 inhibitor CD123 CAR-T EED inhibitor TIM3 antagonist MCL1 inhibitor BAFF-R inhibitor CD19 CAR-T Indication(s) Sickle cell anemia Haematological malignancy Haematological malignancy Acute myeloid leukaemia Cancers Low risk myelodysplastic syndrome Acute myeloid leukaemia (combo) Haematological malignancy Cancers Multiple myeloma DLBCL and adult ALL Mechanism NS4B inhibitor Indication(s) Dengue Malaria prophylaxis Malaria, uncomplicated Respiratory diseases Respiratory diseases Diabetic eye diseases NOVARTIS | Reimagining Medicine

View entire presentation